Finally, a network perturbation analysis suggested that the pharmacological modulation of Egr1 may have the potential to revert many disease- and gender-associated transcriptomic changes in the Alzheimer model toward the wildtype control phenotype, in line with previous reports on protective effects of Egr1 inhibition in other AD model systems. The gene discussed is EGR1; the disease is Alzheimer disease.